AstraZeneca is set to revolutionize its oncology division with a bold $50 billion investment in U.S. manufacturing by 2030 and the acquisition of Modella AI, aimed at enhancing drug development through advanced artificial intelligence. This strategic move comes as AstraZeneca's oncology segment has already reported a 16% year-over-year sales growth, bolstering a projected revenue of $15.76 billion in its forthcoming earnings report. Despite a recent dip in stock value leading to its removal from the Nasdaq-100 index, the company is reinforcing its position for robust growth in the pharmaceutical market.
“AstraZeneca (AZN) has acquired the biomedical artificial intelligence company Modella AI to accelerate the development of cancer therapies. The pharma giant will use Modella AI's multi-modal foundation models and AI agents in its oncology R&D space, enabling the generation of new biological and clinical insights, as well as greater automation, scalability, and consistency across data-intensive workflows, per a news release.”
“We believe AstraZeneca's robust on-market portfolio and sector-leading late-stage pipeline provide an attractive growth profile. Moreover, we believe the company can build on its long track record of a productive research and development program, thanks to its innovative culture and exceptional management team.”
“CEO Pascal Soriot is one of the industry’s best executives, and he has cultivated a deep bench of talent, a robust decision-making framework and a differentiated R&D culture that should drive strong growth for years to come, in our view.”
“This opened a window for us to purchase shares of this company at a price well below our estimate of its intrinsic value.”
“2020 AstraZeneca Alexion $39 AstraZeneca's largest ever deal to diversify away from its cancer business, betting on rare-disease and immunology drugs.”
“The biggest risers on the FTSE 100 were Glencore, up 14.0p at 484.2p, Marks & Spencer, up 9.57p at 355.57p, AstraZeneca, up 338.0p at 14,346.0p, Rio Tinto, up 141.0p at 6,355.0p.”
“Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 10, 2026. The company's upcoming EPS is projected at $1.09, signifying a 3.81% increase compared to the same quarter of the previous year.”
“Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $15.76 billion, up 5.81% from the year-ago period.”
“Astrazeneca is holding a Zacks Rank of #3 (Hold) right now.”
“In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.59 per share and a revenue of $58.73 billion, indicating changes of +11.68% and 0%, respectively, from the former year.”
“AZN's Imfinzi generated sales of $4.32 billion in the first nine months of 2025, up 25%, driven by demand growth in lung and liver cancer indications.”
“The introduction of the IlluminAI assistant at AstraZeneca has streamlined how we approach brand launch planning. Our teams can ask natural-language questions about forecast drivers and receive insights grounded in patient forecast models and revenue data.”
